Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionBrown Advisory Inc
Latest Disclosed Ownership36,225 shares
Latest Disclosed Value $ 2,341,196
Brown Advisory Inc reports 0.99% increase in ownership of HALO / Halozyme Therapeutics, Inc.

On May 15, 2026 - Brown Advisory Inc filed a 13F-HR form disclosing ownership of 36,225 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $2,341,222 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 35,870 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of 0.99% during the quarter. The current value of the position is $2,591,174 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 36,225 355 0.99 2,341 -3.02 0.0017
2026-02-13 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 35,870 905 2.59 2,414 -5.85 0.0034
2025-11-14 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 34,965 -92 -0.26 2,564 40.65 0.0033
2025-08-13 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 35,057 224 0.64 1,824 -17.96 0.0024
2025-04-30 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 34,833 -5,032 -12.62 2,223 16.64 0.0032
2025-02-14 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 39,865 19,002 91.08 1,906 59.55 0.0024
2024-11-13 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 20,863 19 0.09 1,194 9.44 0.0015
2024-08-14 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 20,844 0 0.00 1,091 28.81 0.0014
2024-04-24 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 20,844 -116 -0.55 848 9.43 0.0011
2024-02-08 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 20,960 149 0.72 775 -2.52 0.0011
2023-10-25 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 20,811 0 0.00 795 5.87 0.0013
2023-07-31 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 20,811 0 0.00 751 -5.54 0.0012
2023-05-08 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 20,811 -20,602 -49.75 795 -66.30 0.0013
2023-02-13 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 41,413 0 0.00 2,356 43.92 0.0044
2022-11-14 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 41,413 0 0.00 1,637 -10.15 0.0032
2022-11-14 2022-06-30 13F/A-2 HALOZYME THERAPEUTICS COM 40637H109 41,413 0 0.00 1,822 10.29 0.0034
2022-09-13 2022-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 41,413 0 1,822 0.0032
2022-08-02 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 41,413 0 1,822 0.0029
2022-11-14 2022-03-31 13F/A-2 HALOZYME THERAPEUTICS COM 40637H109 41,413 -121 -0.29 1,652 -1.08 0.0025
2022-09-13 2022-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 41,413 -121 1,652 0.0023
2022-05-09 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 41,413 -121 1,652 0.0022
2022-01-27 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 41,534 102 0.25 1,670 -0.89 0.0021
2021-11-12 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 41,432 19 0.05 1,685 -10.42 0.0025
2021-07-29 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 41,413 -20,990 -33.64 1,881 -27.71 0.0028
2021-05-14 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 62,403 -37 -0.06 2,602 -2.44 0.0044
2021-02-12 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 62,440 108 0.17 2,667 62.82 0.0047
2020-11-16 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 62,332 26,302 73.00 1,638 69.57 0.0034
2020-08-14 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 36,030 0 0.00 966 49.07 0.0023
2020-05-15 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 36,030 0 0.00 648 1.41 0.0020
2020-02-14 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 36,030 0 0.00 639 14.31 0.0016
2019-11-14 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 36,030 0 0.00 559 -9.69 0.0016
2019-08-12 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 36,030 -74,500 -67.40 619 -65.22 0.0018
2019-05-15 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 110,530 0 0.00 1,780 10.08 0.0050
2019-02-13 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 110,530 0 0.00 1,617 -19.47 0.0054
2018-11-13 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 110,530 0 0.00 2,008 7.67 0.0057
2018-08-10 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 110,530 0 0.00 1,865 -13.86 0.0057
2018-06-28 2018-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 110,530 -40,917 -27.02 2,165 -29.43 0.0070
2018-05-14 2018-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 11,030 -140,417 216
2018-02-12 2017-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 151,447 -38,089 -20.10 3,068 -6.80 0.0097
2017-11-13 2017-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 189,536 -10,907 -5.44 3,292 28.09 0.0109
2017-08-14 2017-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 200,443 1,605 0.81 2,570 -0.27 0.0079
2017-05-15 2017-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 198,838 22,391 12.69 2,577 47.76 0.0088
2017-02-13 2016-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 176,447 -87,913 -33.26 1,744 -45.38 0.0062
2016-11-14 2016-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 264,360 -2,500 -0.94 3,193 38.65 0.0110
2016-08-09 2016-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 266,860 206,585 342.74 2,303 303.33 0.0081
2016-05-13 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 60,275 60,275 571 0.0020
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.